COMMUNIQUÉS West-GlobeNewswire

Ipsen enregistre une forte dynamique commerciale au cours des neuf premiers mois de l'année 2025 et revoit à la hausse ses prévisions pour l'exercice en cours
22/10/2025
Croissance du chiffre d’affaires du Groupe de 12,1 % à taux de change constant 1 au cours des neuf premiers mois de l’année 2025, ou 9,6 % en données publiées, portée par les trois aires thérapeutiques et incluant les [...]
Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance
22/10/2025
Year-to-date total sales growth of 12.1% at CER 1 , or 9.6% as reported, driven by all three therapeutic areas and including strong performance from Iqirvo®, Bylvay® and Somatuline® Further upgrade of full-year 2025 [...]
Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)
22/10/2025
Cosentyx® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 52 1 Trial showed reduction in annual cumulative steroid dose vs placebo through Week 52; [...]
SPINEWAY : Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP en Australie
22/10/2025
Ecully, le 22 octobre 2025 – 8h30 SPINEWAY Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP de Spineway en Australie Spineway, spécialiste des implants innovants pour le traitement des pathologies [...]
Aveanna Announces Pricing of Secondary Offering of Common Stock
22/10/2025
ATLANTA, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, [...]
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
22/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and [...]
Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series
22/10/2025
SAN CARLOS, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it will participate in Citi’s SMID Biotech C-Suite [...]
Fairhaven Health Highlights Science-Driven Solutions for Women During Menopause Awareness Month
21/10/2025
MIDDLETOWN, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) -- October marks Menopause Awareness Month, a time to focus on the physical and emotional changes that affect more than 1 million American women each year. Fairhaven [...]
Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
21/10/2025
BOSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine [...]
RAPT Therapeutics Announces Proposed Public Offering of Common Stock
21/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and [...]
NurExone Invited Presenter at Precision EV Forum in Cambridge, UK
21/10/2025
Highlighting Regulatory and Clinical Leadership in Regenerative Exosome Therapies TORONTO and HAIFA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
21/10/2025
CONSHOHOCKEN, Pa., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]
InspireMD to Announce Third Quarter 2025 Financial Results
21/10/2025
MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its third quarter 2025 [...]
Eagle Pharmaceuticals Announces Results of 2025 Annual Meeting of Stockholders
21/10/2025
WOODCLIFF LAKE, N.J., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) is pleased to announce the voting results for each of the matters presented at the Company’s [...]
Inotiv, Inc. to Participate in Three Investor Conferences in November 2025
21/10/2025
WEST LAFAYETTE, Ind., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and [...]
Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity
21/10/2025
Results show maximum placebo-adjusted weight loss of 4.6% with 12% treatment discontinuation due to adverse events Asymptomatic, reversible grade 3 liver enzyme elevations occurred in three participants during post- [...]
Intuitive Announces Third Quarter Earnings
21/10/2025
SUNNYVALE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial [...]
Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025
21/10/2025
CARLSBAD, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended September 30, 2025, before the [...]
Ceribell to Report Third Quarter 2025 Financial Results on November 4, 2025
21/10/2025
SUNNYVALE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]

Pages